Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/unpaywall/clinical-monitoring-infliximab-biosimilar-ct-p13-in-the-treatment-of-JWUeD4SNuc
References (42)
-
T. Yao (2002)
[Inflammatory bowel diseases].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 91 2
-
F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs, G. Assche, I. Hoffman, K. Steen, S. Vermeire, P. Rutgeerts (2008)
Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohortGut, 58
-
Maureen Lawson, Adrian Thomas, A. Akobeng (2006)
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.The Cochrane database of systematic reviews, 3
-
G. Järnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Karlén, C. Grännö, M. Vilién, M. Ström, Å. Danielsson, H. Verbaan, P. Hellström, A. Magnuson, B. Curman (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.Gastroenterology, 128 7
-
S. Targan, S. Hanauer, S. Deventer, L. Mayer, D. Present, T. Braakman, K. DeWoody, T. Schaible, P. Rutgeerts (1997)
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 337
-
S. Park, Young-Ho Kim, J. Lee, H. Kwon, S. Lee, D. Park, H. Kim, J. Cheon, J. Im, You Kim, S. Lee, Sang Lee (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in KoreaExpert Review of Gastroenterology & Hepatology, 9
-
H. Grabowski, Rahul Guha, Maria Salgado (2014)
Biosimilar competition: lessons from EuropeNature Reviews Drug Discovery, 13
-
(2015)
Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report -
MolnarT, FarkasK, RutkaM (2015)
Efficacy of the new infliximab biomarker CT-P13 induction therapy on mucosal healing in ulcerative colitis patients.J Crohns Colitis, 9
-
W. Park, P. Hrycaj, S. Jeka, V. Kovalenko, G. Lysenko, P. Miranda, H. Mikažāne, S. Gutiérrez-Ureña, M. Lim, Yeon-Ah Lee, Sang Lee, Houng Kim, D. Yoo, J. Braun (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 72
-
S. Plevy, C. Landers, J. Prehn, N. Carramanzana, R. Deem, D. Shealy, S. Targan (1997)
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.Journal of immunology, 159 12
-
J. Kierkuś (2015)
Tu1081 Preliminary Assessment of Efficacy and Safety of Switching Between Originator and Biosimilar Infliximab in Paediatric Crohn Disease PatientsGastroenterology, 148
-
D. Baumgart (2012)
Crohn's disease and ulcerative colitis : from epidemiology and immunobiology to a rational diagnostic and therapeutic approach -
A. Cheifetz, M. Smedley, S. Martin, M. Reiter, G. Leone, L. Mayer, S. Plevy (2003)
The Incidence and Management of Infusion Reactions to Infliximab: A Large Center ExperienceAmerican Journal of Gastroenterology, 98
-
S. Vermeire, G. Assche, P. Rutgeerts (2004)
C-Reactive Protein as a Marker for Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 10
-
S. Targan, S. Hanauer, S. Deventer, L. Mayer, D. Present, T. Braakman, K. DeWoody, T. Schaible, P. Rutgeerts (1997)
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.The New England journal of medicine, 337 15
-
K. Gecse, B. Lovász, K. Farkas, J. Banai, L. Bene, B. Gasztonyi, P. Golovics, T. Kristof, L. Lakatos, Á. Csontos, M. Juhász, F. Nagy, K. Palatka, M. Papp, Á. Patai, L. Lakner, Á. Salamon, T. Szamosi, Z. Szepes, G. Tóth, Á. Vincze, B. Szalay, T. Molnár, P. Lakatos (2016)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.Journal of Crohn's & colitis, 10 2
-
Dawn Wiese, B. Lashner, D. Seidner (2008)
Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 23 5
-
GecseK, FarkasK, LovaszB (2015)
Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.J Crohns Colitis, 9
-
R. Vădan, L. Gheorghe, A. Constantinescu, C. Gheorghe (2011)
The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.Clinical nutrition, 30 1
-
Ea Fagan, Rf Dyck, P. Maton, H. Hodgson, V. Chadwick, A. Petrie, M. Pepys (1982)
Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitisEuropean Journal of Clinical Investigation, 12
-
Judith Pichler, A. Hanslik, Wolf Huber, C. Aufricht, Bettina Bidmon-Fliegenschnee (2014)
Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone healthActa Paediatrica, 103
-
Y. Jung, D. Park, Y. Kim, Ji Lee, P. Seo, J. Cheon, H. Kang, Ji Kim (2015)
Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter studyJournal of Gastroenterology and Hepatology, 30
-
K. Gecse, K. Farkas, B. Lovász, J. Banai, L. Bene, B. Gasztonyi, P. Golovics, T. Kristof, L. Lakatos, P. Miheller, F. Nagy, K. Palatka, M. Papp, V. Patai, Á. Salamon, T. Szamosi, Z. Szepes, T. Tóth, Á. Vincze, T. Molnár, P. Lakatos (2015)
Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohortZeitschrift Fur Gastroenterologie, 53
-
D. Baumgart, W. Sandborn (2007)
Inflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet, 369
-
G. Assche, A. Dignass, J. Panés, L. Beaugerie, J. Karagiannis, M. Allez, T. Ochsenkühn, T. Orchard, G. Rogler, E. Louis, L. Kupčinskas, G. Mantzaris, S. Travis, E. Stange (2006)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.Journal of Crohn's & colitis, 4 1
-
G. Fiorino, S. Danese (2014)
The biosimilar road in inflammatory bowel disease: the right way?Best practice & research. Clinical gastroenterology, 28 3
-
D. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanovic, M. Abello-Banfi, S. Gutiérrez-Ureña, Luis Morales-Olazabal, M. Tee, R. Jimenez, Omid Zamani, Sang Lee, Houng Kim, W. Park, U. Müller-Ladner (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 72
-
L. Brandt (1998)
Book Review Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, diagnosis, management Sixth edition. Edited by Mark Feldman, Bruce F. Scharschmidt, and Marvin H. Sleisenger, with Samuel Klein. 2046 pp. in two volumes, illustrated. Philadelphia, W.B. Saunders, 1998. $195. 0The New England Journal of Medicine, 339
-
(2015)
Tumor necrosis factor alpha inhibitors: an overview of adverse effects Available from: http:// www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors- an-overview-of-adverse-effects -
HanauerSB, FeaganBG, LichtensteinGR (2002)
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.Lancet, 359
-
A. Amiot, L. Peyrin-Biroulet (2015)
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseasesTherapeutic Advances in Gastroenterology, 8
-
P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. Hanauer, G. Lichtenstein, W. Villiers, D. Present, B. Sands, J. Colombel (2005)
Infliximab for induction and maintenance therapy for ulcerative colitis.The New England journal of medicine, 353 23
-
Tephan, Argan, tephen, H. B, Anauer, A. R., Van, Ogezand, Aniel, P. K., Odolsky, Anja, Raakman, Homas, S. F., Chaible, Ander, H. J., Eventer (1999)
Infliximab for the treatment of fistulas in patients with Crohn's disease.The New England journal of medicine, 340 18
-
A. Dignass, R. Eliakim, F. Magro, C. Maaser, Y. Chowers, K. Geboes, G. Mantzaris, W. Reinisch, J. Colombel, S. Vermeire, S. Travis, J. Lindsay, G. Assche (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.Journal of Crohn's & colitis, 6 10
-
P. Rutgeerts, G. Assche, S. Vermeire (2006)
Review article: infliximab therapy for inflammatory bowel disease – seven years onAlimentary Pharmacology & Therapeutics, 23
-
Ak Pithawa (2007)
Sleisenger and Fordtran's Gastrointestinal and Liver Disease: pathophysiology, diagnosis, managementMedical journal, Armed Forces India, 63
-
(2015)
Tumor necrosis factor alpha inhibitors: an overview of adverse effects; 2014 -
(2015)
First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population -
Yun-Seong Kang, H. Moon, Seung Lee, Y. Lim, H. Kang (2015)
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case SeriesDigestive Diseases and Sciences, 60
-
K. Farkas, M. Rutka, P. Golovics, Z. Végh, B. Lovász, T. Nyári, K. Gecse, M. Kolář, M. Bortlík, D. Ďuricová, N. Machková, V. Hrubá, M. Lukas, K. Mitrová, K. Malíčková, A. Bálint, F. Nagy, R. Bor, Á. Milassin, Z. Szepes, K. Palatka, P. Lakatos, M. Lukáš, T. Molnár (2016)
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.Journal of Crohn's & colitis, 10 11
-
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group
- Publisher
- Unpaywall
- ISSN
- 0036-5521
- DOI
- 10.3109/00365521.2016.1149883
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Scandinavian Journal of Gastroenterology – Unpaywall
Published: Mar 22, 2016